机构:[1]Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China[2]Shanxi Eye Hospital, Taiyuan, Shanxi Province, China[3]Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, China[4]Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University, Dalian, China大连医科大学附属第一医院[5]Department of Ophthalmology, Jiangsu Province Hospital, the First Affiliated Hospital With Nanjing Medical University, Jiangsu Women and Children Health Hospital, Nanjing, Jiangsu, China江苏省人民医院[6]Department of Ophthalmology, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Peking University Third Hospital, Beijing, China[7]The Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China北京朝阳医院[8]Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China[9]Shanghai Haohai Biological Technology Co. Ltd., Shanghai, China
BackgroundTo evaluate the efficacy and safety of a linearly cross-linked sodium hyaluronic acid (HA) hydrogel used as a retinal patch in the treatment of rhegmatogenous retinal detachment (RRD).MethodsThis multicenter, randomised, parallel-controlled trial included 313 participants diagnosed with RRD classified as PVR grade A or B, excluding those with giant retinal tears (defined as tears spanning more than one quadrant). Participants were randomly assigned to either an experimental group or a control group. Following laser photocoagulation to retinal breaks, the experimental group received intraocular tamponade with a combination of linearly cross-linked sodium HA hydrogel and sterile air, whereas the control group received intraocular tamponade with perfluoropropane gas (C3F8). According to the intention-to-treat (ITT) principle, the final analysis included 155 subjects in the experimental group and 158 in the control group. The primary outcome measure was the retinal reattachment rate within 24 weeks postoperatively.ResultsAt 24 weeks, retinal reattachment rates were 91.8% in the experimental group and 91.4% in the control group (p = 0.903), with no statistically significant differences at any follow-up time point. Additionally, there were no significant differences between the two groups regarding best-corrected visual acuity (BCVA), intraocular pressure (IOP), or postoperative complications.ConclusionsThe application of linearly cross-linked sodium HA hydrogel as a retinal patch demonstrated effectiveness comparable to traditional gas tamponade in the treatment of RRD. Furthermore, this method exhibited a favourable safety profile. The technique obviates the need for postoperative prone positioning, significantly improving the patient's postoperative comfort and quality of life.Trial RegistrationChinese Clinical Trial Registry: ChiCTR2000037030
基金:
Tianjin Key Medical Discipline (Specialty) Construction Project, TJYXZDXK-037A, Tianjin Municipal Education
Commission, 2021KJ223.
第一作者机构:[1]Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Liu Boshi,Wang Manqiao,Tan Liangzhang,et al.Hyaluronic Acid Hydrogel as a Retinal Patch in the Treatment of Rhegmatogenous Retinal Detachment: A Multicenter Randomised Parallel-Controlled Trial[J].CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY.2025,doi:10.1111/ceo.14570.
APA:
Liu, Boshi,Wang, Manqiao,Tan, Liangzhang,Pazo, Emmanuel Eric,Yuan, Lili...&Li, Xiaorong.(2025).Hyaluronic Acid Hydrogel as a Retinal Patch in the Treatment of Rhegmatogenous Retinal Detachment: A Multicenter Randomised Parallel-Controlled Trial.CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY,,
MLA:
Liu, Boshi,et al."Hyaluronic Acid Hydrogel as a Retinal Patch in the Treatment of Rhegmatogenous Retinal Detachment: A Multicenter Randomised Parallel-Controlled Trial".CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY .(2025)